Mortality and delay in effective therapy associated with extended-spectrum β-lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis

Journal of Antimicrobial Chemotherapy

Volumn 60, Issue 5, 2007, Pages 913-920

  Schwaber, Mitchell J ^a   Carmeli, Yehuda ^a,b  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antimicrobial resistance; Bloodstream infection; Gram negative; Outcomes

Indexed keywords

ANTIBIOTIC AGENT; EXTENDED SPECTRUM BETA LACTAMASE;

ANTIBIOTIC RESISTANCE; BACTEREMIA; CONFOUNDING VARIABLE; DRUG EFFICACY; ENTEROBACTERIACEAE; ENZYME SYNTHESIS; HUMAN; INCIDENCE; MEDLINE; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; THERAPY DELAY;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS;

EID: 35448972600     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm318     Document Type: Review

References (37)

1. Rodriguez-Bano J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-94.
2. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42 Suppl 2: S82-9.
3. Ben-Ami R, Schwaber MJ, Navon-Venezia S et al. Influx of extended-spectrum β-lactamase-producing Enterobacteriaceae into the hospital. Clin Infect Dis 2006; 42: 925-34.
4. Schwaber MJ, Raney PM, Rasheed JK et al. Utility of NCCLS guidelines for identifying extended-spectrum β-lactamases in non- Escherichia coli and non-Klebsiella spp. of Enterobacteriaceae. J Clin Microbiol 2004; 42: 294-8.
5. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-85.
6. Schwaber MJ, Navon-Venezia S, Schwartz D et al. High levels of antimicrobial coresistance among extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2005; 49: 2137-9.
7. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36: 1433-7.
8. Cosgrove SE, Sakoulas G, Perencevich EN et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003; 36: 53-9.
9. DiazGranados CA, Zimmer SM, Klein M et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: A meta-analysis. Clin Infect Dis 2005; 41: 327-33.
10. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: A clinical update. Clin Microbiol Rev 2005; 18: 657-86.
11. Ramphal R, Ambrose PG. Extended-spectrum β-lactamases and clinical outcomes: Current data. Clin Infect Dis 2006; 42 Suppl 4: S164-72.
12. Schwaber MJ, Navon-Venezia S, Kaye KS et al. Clinical and economic impact of bacteremia with extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50: 1257-62.
13. Cephalosporins-EUCAST clinical breakpoints; 2006-03-31 (v 1.1) footnote 2. http://www.srga.org/eucastwt/MICTAB/MICcephalosporins.html (30 August 2007, date last accessed).
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
15. Sterne JA, Egger M. Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis. J Clin Epidemiol 2001; 54: 1046-55.
16. Hayashino Y, Noguchi Y, Fukui T.. Systematic evaluation and comparison of statistical tests tor publication bias. J Epidemiol 2005; 15 235-43.
17. Tumbarello M, Spanu T, Sanguinetti M et al. Bloodstream infections caused by extended-spectrum-β-lactamase-producting Klebsiella pneumoniae, risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006; 50: 498-504.
18. Marra AR, Wey SB, Castelo A et al. Nosocomial bloodstream infections caused by Klebsiella pneumoniae: Impact of extended-spectrum β-lactamase (ESBL) production on clinical outcome in a hospital with high ESBL prevalence. BMC Infect Dis 2006; 6 24.
19. Endimiani A, Luzzaro F, Brigante G et al. Proteus mirabilis bloodstream infections: Risk factors and treatment outcome related to the expression of extended-spectrum β-lactamases: Antimicrob Agents Chemother 2005; 49: 2598-605.
20. Zaoutis TE, Goyal M, Chu JH et al. Risk factors for and out-comes of bloodstream infection caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella species in children. Pediatrics 2005; 115: 942-9.
21. Blomberg B, Jureen R, Manji KP et al. High rate of fatal cases of pediatric septicemia caused by gram-negative bacteria with extended-spectrum β-lactamases in Dar es Salaam, Tanzania. J Clin Microbiol 2005; 43: 745-9.
22. Panhotra BR, Saxena AK, Al-Ghamdi AM. Extended-spectrum β-lactamase-producing Klebsiella pneumoniae hospital acquired bacteremia. Risk factors and clinical outcome. Saudi Med J 2004; 25: 1871-6.
23. Kang CI, Kim SH, Kim DM et al. Risk factors for and clinical outcomes of bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2004; 25: 860-7.
24. Kim BN, Woo JH, Kim MN et al. Clinical implications of extended-spectrum β-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect 2002; 52: 99-106.
25. Du B, Long Y, Liu H et al. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: Risk factors and clinicad outcome. Intensive Care Med 2002; 28: 1718-23.
26. Kim YK, Pai H, Lee HJ et al. Bloodstream infections by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in children: Epidemiology and clinical outcome. Antimicrob Agents Chemother 2002; 46: 1481-91.
27. Borer A, Gilad J, Menashe G et al. Extended-spectrum β-lactamase-producing Enterobacteriaceae strains in community-acquired bacteremia in Southern Israel. Med Sci Monit 2002; 8: CR44-7.
28. Ho PL, Chan WM, Tsang KW et al. Bacteremia caused by Escherichia coli producing extended-spectrum β-lactamase: A case-control study of risk factors and outcomes. Scand J Infect Dis 2002; 34: 567-73.
29. Menashe G, Borer A, Yagupsky P et al. Clinical significance and impact on mortality of extended-spectrum β-lactamase-producing Enterobacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001; 33: 188-93.
30. Pena C, Pujol M, Ardanuy C et al. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum β-lactamase. J Hosp Infect 2001; 47: 53-9.
31. Ariffn H, Navaratnam P, Mohamed M et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis 2000; 4: 21-5.
32. Harbarth S, Garbino, J, Pugin J et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115 529-35.
33. Iregui M, Ward S, Sherman G et al. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122: 262-8.
34. Paterson DL, Ko WC, Von Gottberg A et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: Implications of production of exterided-spectrum β-lactamases. Clin Infect Dis 2004; 39: 31-7.
35. Zimhony O, Chmelnitsky I, Bardenstein R et al. Endocarditis caused by extended-spectrum-β-lactamase-producing Klebsiella pneumoniae: emergence of resistance to ciprofloxacin and piperacillin-tazobactam during treatment despite initial susceptibility. Antimicrob Agents Chemother 2006; 50: 3179-82.
36. Sahly H, Aucken H, Benedi VJ et al. Increased serum resistance in Klebsiella pneumoniae strains producing extended-spectrum β-lactamases. Antimicrob Agents Chemother 2004; 48: 3477-82.
37. Hay A, Navon-Venezia S, Sahly H et al. Association between extended-spectrum β-lactamase (ESBL) production and serum resistance (SR) in Klebsiella pneumoniae (Kpn) and transfer of SR by SHV-12-endcoding plasmid. In: Program and abstracts of the 44th Annual Meeting of the Infectious Diseases Society of America. Chicago: University of Chicago Press, 2006.